The SPLE blueprint is four domains with published weights: Basic Biomedical Sciences 10%, Pharmaceutical Sciences 35%, Social, Behavioral and Administrative Sciences 20%, and Clinical Sciences 35%. Those four numbers are the single most useful planning tool you have, and most candidates use them only to decide that "clinical is the big one" before returning to whatever they were revising anyway. This guide takes each domain in turn, and the Myndaq SPLE course follows the same blueprint.
Every figure in this guide is checked against the official SCFHS examination content guideline linked below - verified on 13 September 2026; re-verified on 16 September 2026.
Clinical Sciences - 35%
This is applied pharmacotherapy, and it is the largest single block along with Pharmaceutical Sciences. The blueprint does not name organ systems or diseases; it lists what you must be able to do. At its centre is clinical pharmacology and therapeutic decision-making: applying pathophysiology, making therapy recommendations, checking contraindications, duplications and interactions, knowing when to refer, and monitoring therapy. Around that sit drug information and evidence-based practice, clinical pharmacokinetics and therapeutic drug monitoring, pharmacogenomics, disease prevention and immunisation, patient assessment and laboratory values, nonprescription and natural product therapies, patient counselling, and pharmacotherapy in special populations such as neonates, pregnant women, lactating mothers and older adults.
The questions that separate candidates here are rarely "what is the mechanism of X". They are scenario items where two options are pharmacologically defensible and one is right for this patient - the renally-impaired one, the pregnant one, the one already on an interacting drug. Practise reading the stem for the constraint before you read the options.
Pharmaceutical Sciences - 35%
The other 35%, and equal in weight to Clinical Sciences - the blueprint gives each six competency areas and does not rank them by breadth. It runs from medicinal chemistry, drug classes and mechanisms, adverse effects and interactions, toxicology and antidotes, and pharmacognosy and dietary supplements, through pharmacokinetics, bioavailability and pharmacodynamics, to the formulation side: dosage forms, stability and biopharmaceutics, pharmaceutical calculations, sterile and nonsterile compounding, and sterile admixture technique.
Calculations deserve separate treatment. The arithmetic is almost never difficult. Setting the problem up quickly is the skill, and it decays fast without practice. At roughly 72 seconds per question (each part is 100 questions in 120 minutes), a calculation you have to reason out from first principles costs you two questions' worth of time, not one. Drill dosing, dilutions, infusion rates and compounding until the setup is automatic rather than reasoned.
Social, Behavioral and Administrative Sciences - 20%
Part of this domain is Saudi-specific: the blueprint asks directly about the organisations involved in healthcare delivery in the Kingdom and the factors that influence healthcare delivery in Saudi Arabia, and the guide's general reference list includes Saudi Food and Drug Authority (SFDA) and Ministry of Health sources, although SCFHS describes that list as a study aid only. In outline, the domain covers the Saudi healthcare delivery organisations and the social, political and economic factors that shape them, public health, pharmacoepidemiology, pharmacovigilance and medication safety, pharmacoeconomics, pharmacy practice management, pharmacy law and regulatory affairs, biostatistics and research design, ethical decision-making, professional communication, adherence and behaviour change, and dispensing systems, pharmacy informatics and medication-error prevention.
You will not find the Saudi health-system material in an international pharmacy textbook. The law competencies are written in general terms - how the authority, regulatory agencies and health institutions' policies govern prescriptions, controlled substances and nonprescription medications - so if you have practised elsewhere, check each rule you know against Saudi sources rather than assuming it carries over. This is where jurisdictions differ in detail while sounding similar in outline.
Twenty per cent is roughly forty questions. That is a serious block of marks, and much of it - law, ethics, practice management, biostatistics - is a finite body of material that rewards concentrated revision.
Basic Biomedical Sciences - 10%
Physiology, biochemistry, microbiology related to human disease, and immunology, including the molecular genetics and genomics that underpin pharmacogenomics. Roughly twenty questions.
The temptation is to skip it. Don't, but do not over-invest either. Most of what this domain tests is reinforced by the clinical revision you are doing anyway - understanding the physiology and signal-transduction pathways behind a disease is simultaneously Basic Biomedical and Clinical preparation. Treat it as the foundation you revise through the clinical domains rather than as a separate syllabus, and spend the saved time on the Saudi-specific block.
Turning weights into a study plan
Three rules make the blueprint actually change what you do.
Plan in questions, not topics. Ten per cent sounds dismissible; twenty questions does not. Forty questions on the health system, law, ethics and practice management sounds like what it is - a serious block of marks in the domain whose gaps are usually quickest to close.
Measure by domain, not overall. A single percentage hides the shape of the problem. Two candidates with the same overall practice score can need entirely different months of work, and only a per-domain breakdown tells them which.
Revise the 20% disproportionately early. The clinical domains reward sustained work over months; the Saudi-specific domain rewards a concentrated few weeks and then holds. Doing it early means it is banked while you are still grinding pharmacotherapy, rather than crammed into the last week before you sit the exam.
Quick answers
Are the domain weights fixed for every sitting? The published blueprint gives these weights, but the guide notes that blueprint distributions may differ by up to plus or minus 5% at each level, and that up to 10% of the 200 questions may be pilot questions; it does not explain how pilot questions are treated in scoring. Treat the question counts in this guide as approximate, and confirm the weights in the current SCFHS examination content guideline before planning around them.
Which domain should I start with? If you are internationally educated, start with the Saudi-specific 20% - it is the one that will not improve by accident. If you trained in Saudi Arabia, start with whichever of the two 35% domains your diagnostic is weaker in.
How much detail does the law material go into? SCFHS does not publish the depth of the law questions, but the blueprint lists these competencies: how legal and regulatory principles apply to dispensing, professional services and drug use control; administrative, civil and criminal liability for pharmacists; and how regulatory agencies and institutional policies govern prescriptions, controlled substances and nonprescription medications. The guide's general reference list, which is not split by domain and which SCFHS describes as a study aid only, includes Saudi sources: the SFDA drug list, the SFDA procedures and controls for narcotic drugs and psychotropic substances, a further SFDA PDF link given without a title, and the Ministry of Health page for the list of required immunisations.
Format, pass score and attempt rules are covered in the SPLE exam guide.
